| Document Date: 2012-03-27 13:52:29
Open Document File Size: 182,30 KBShare Result on Facebook
City Reference / / Company Merck & Co. Inc. / AMP / Merck Sharp & Dohme Corp. / / Event FDA Phase / / Facility Laboratory Tests *Sections / Laboratory Tests Across / / IndustryTerm treatment for diabetes / food / / MedicalCondition loss of consciousness / headache / nausea / chronic renal insufficiency / anaphylaxis / Stevens-Johnson syndrome / diabetic ketoacidosis / diarrhea / hypersensitivity / End Stage Renal Disease / end-stage renal disease / constipation / Hypoglycemia / respiratory tract infection / mild renal insufficiency / moderate renal insufficiency / Hepatic Insufficiency / upper respiratory tract infection / abdominal pain / vasculitis / nasopharyngitis / Carcinogenesis / ESRD / diabetes / severe renal insufficiency / serious hypersensitivity / seizure / vomiting / Renal Insufficiency / diabetes mellitus / urticaria / angioedema / pancreatitis / acute pancreatitis / rash / acute renal failure / / MedicalTreatment oral contraceptives / peritoneal dialysis / insulin therapy / hemodialysis / dialysis / / Organization DOSAGE AND ADMINISTRATION / FDA / / / Position investigator / General / / Product pioglitazone / simvastatin / cyclosporine / glucagon / glimepiride / polyethylene glycol / talc / Digoxin / FDAapproved Medication / glyburide / JANUVIA / rosiglitazone / sitagliptin / / Technology alpha / Pharmacokinetics / Pharmacodynamics / dialysis / / URL www.fda.gov/medwatch / /
SocialTag |
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) Tablets Initia